{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:40:35Z","timestamp":1774039235139,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\n Background<\/jats:title>\n There is controversy about the benefit of administering adjuvant therapy to esophageal cancer (EC) patients after preoperative neoadjuvant therapy and surgical treatment. This study aims to investigate the clinical benefit of postoperative adjuvant therapy in EC patients with neoadjuvant therapy and surgery.<\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n The study included EC patients diagnosed from 2007 to 2020 in the Surveillance, Epidemiology, and End Results (SEER) database. Patients who received neoadjuvant therapy (NCRT) were defined as those who underwent neoadjuvant chemotherapy or neoadjuvant radiotherapy before surgery, while patients who received adjuvant therapy (ACRT) were defined as those who underwent adjuvant chemotherapy or adjuvant radiotherapy after surgery. Propensity score matching (PSM) method was employed to establish matched cohorts, and Kaplan-Meier analysis, COX regression model, and Fine-Gray model were used for survival analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The study included a total of 5805 EC patients, with 837 (14.4%) in the ACRT group and 4968 (85.4%) in the no-ACRT group. After PSM, a cohort of 1660 patients who received NCRT was enrolled for analysis, with 830 patients in each group. Kaplan-Meier analysis revealed no significant differences between the two groups in terms of median overall survival (OS) (34.0 vs. 36.0 months,\n p<\/jats:italic>\n = 0.89) or cancer-specific survival (CSS) (40.0 vs. 49.0 months,\n p<\/jats:italic>\n = 0.16). Multivariate Cox models and Fine-Gray models indicated that ACRT was not a predictive factor for OS or CSS (\n p<\/jats:italic>\n > 0.05). Subgroup analysis for CSS suggested a protective effect of ACRT in the N2 (Cox model: HR = 0.640,\n p<\/jats:italic>\n = 0.090; Fine-Gray model: HR = 0.636,\n p<\/jats:italic>\n = 0.081) and the N3 subgroup (Cox model: HR = 0.302,\n p<\/jats:italic>\n = 0.018; Fine-Gray model: HR = 0.306,\n p<\/jats:italic>\n = 0.034).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Only for esophageal cancer patients with a more advanced N stage, postoperative adjuvant therapy after completing neoadjuvant therapy and curative surgical treatment may be beneficial.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0304937","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:32:12Z","timestamp":1732023132000},"page":"e0304937","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: A retrospective cohort study"],"prefix":"10.1371","volume":"19","author":[{"given":"Weiyi","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-417X","authenticated-orcid":true,"given":"Renwang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"3","key":"pone.0304937.ref001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"21","key":"pone.0304937.ref002","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa022343","article-title":"Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus","volume":"347","author":"B F Hulscher Jan","year":"2002","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0304937.ref003","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1200\/JCO.20.00866","article-title":"Treatment of Locally Advanced Esophageal Carcinoma ASCO Guideline.","volume":"38","author":"A Shah Manish","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0304937.ref004","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.thorsurg.2022.06.003","article-title":"Neoadjuvant Therapy in Esophageal Cancer.","volume":"32","author":"S Lewis","year":"2022","journal-title":"Thorac Surg Clin"},{"issue":"7","key":"pone.0304937.ref005","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/gut.2003.025080","article-title":"Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis","volume":"53","author":"F Fiorica","year":"2004","journal-title":"Gut"},{"issue":"3","key":"pone.0304937.ref006","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","article-title":"Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis","volume":"8","author":"V Gebski","year":"2007","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0304937.ref007","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9610(03)00066-7","article-title":"A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer","volume":"185","author":"JD Urschel","year":"2003","journal-title":"Am J Surg"},{"key":"pone.0304937.ref008","author":"EL B\u00e9dard","year":"2001","journal-title":"The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma"},{"issue":"24","key":"pone.0304937.ref009","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2006.10.4760","article-title":"Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.","volume":"25","author":"DP Kelsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"pone.0304937.ref010","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer.","volume":"27","author":"WH Allum","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"pone.0304937.ref011","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.","volume":"16","author":"J Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"pone.0304937.ref012","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0022-5223(03)01025-0","article-title":"Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma.","volume":"126","author":"TW Rice","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"pone.0304937.ref013","first-page":"153","article-title":"Current management of esophageal squamous-cell carcinoma in Japan and other countries","volume":"3","author":"Katsuhiko Higuchi","year":"2009","journal-title":"Gastrointest Cancer Res"},{"issue":"1","key":"pone.0304937.ref014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SLA.0000000000005227","article-title":"Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis","volume":"275","author":"Y Lee","year":"2022","journal-title":"Ann Surg"},{"key":"pone.0304937.ref015","doi-asserted-by":"crossref","first-page":"897476","DOI":"10.3389\/fonc.2022.897476","article-title":"No survival benefit could be obtained from adjuvant radiotherapy in esophageal cancer treated with neoadjuvant chemotherapy followed by surgery: A SEER-based analysis","volume":"12","author":"SY Zheng","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"pone.0304937.ref016","doi-asserted-by":"crossref","first-page":"e32925","DOI":"10.1097\/MD.0000000000032925","article-title":"Surgery and postoperative radiotherapy affect the prognosis of esophageal cancer: A SEER analysis","volume":"102","author":"W Yang","year":"2023","journal-title":"Medicine (Baltimore)."},{"key":"pone.0304937.ref017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1741-7015-2-35","article-title":"Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis","volume":"2","author":"RA Malthaner","year":"2004","journal-title":"BMC Med"},{"issue":"3","key":"pone.0304937.ref018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000001905","article-title":"Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis","volume":"265","author":"S Pasquali","year":"2017","journal-title":"Ann Surg"},{"key":"pone.0304937.ref019","article-title":"Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis.","volume":"42","author":"N Fan","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"2","key":"pone.0304937.ref020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10147-021-02056-x","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of locally advanced esophageal cancer: a population-based analysis","volume":"27","author":"WX Qi","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"9864","key":"pone.0304937.ref021","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma.","volume":"381","author":"A Pennathur","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"pone.0304937.ref022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clon.2014.05.015","article-title":"Role of chemoradiotherapy in oesophageal cancer\u2014adjuvant and neoadjuvant therapy.","volume":"26","author":"S Gwynne","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"3","key":"pone.0304937.ref023","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10388-020-00811-z","article-title":"The role of adjuvant chemotherapy in esophageal cancer patients after neoadjuvant chemotherapy plus surgery","volume":"18","author":"N Matsuura","year":"2021","journal-title":"Esophagus"},{"issue":"4","key":"pone.0304937.ref024","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.athoracsur.2021.08.068","article-title":"Adjuvant Chemotherapy for Node-positive Esophageal Squamous Cell Carcinoma Improves Survival.","volume":"114","author":"SK Feng","year":"2022","journal-title":"Ann Thorac Surg"},{"issue":"27","key":"pone.0304937.ref025","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.","volume":"36","author":"Hong Yang","year":"2018","journal-title":"J Clin Oncol."},{"issue":"4","key":"pone.0304937.ref026","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jso.10175","article-title":"Prospective analysis of quality of life after surgical resection for esophageal cancer: preliminary results","volume":"81","author":"JA Brooks","year":"2002","journal-title":"J Surg Oncol"},{"issue":"4","key":"pone.0304937.ref027","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.athoracsur.2006.11.061","article-title":"Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis","volume":"83","author":"AJ Graham","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"pone.0304937.ref028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14740338.2021.1955100","article-title":"The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy","volume":"21","author":"G Ikeda","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"pone.0304937.ref029","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"M Ychou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0304937.ref030","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jgh.16156","article-title":"Risk and prognosis of secondary thoracic cancers after radiation therapy for esophageal cancer","volume":"38","author":"H Yi","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"pone.0304937.ref031","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2018.10.024","article-title":"Characterizing Spatial Lung Function for Esophageal Cancer Patients Undergoing Radiation Therapy","volume":"103","author":"A Pinder-Arabpour","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"pone.0304937.ref032","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jtho.2020.06.014","article-title":"Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer.","volume":"15","author":"X Wang","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"4","key":"pone.0304937.ref033","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/gutjnl-2021-324060","article-title":"Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial","volume":"71","author":"R Sundar","year":"2022","journal-title":"Gut"},{"key":"pone.0304937.ref034","article-title":"An off-the-shelf bioadhesive patch for sutureless repair of gastrointestinal defects","author":"J Wu","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"13","key":"pone.0304937.ref035","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"RJ Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"pone.0304937.ref036","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1097\/CM9.0000000000002371","article-title":"Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy","volume":"135","author":"Y Yan","year":"2022","journal-title":"Chin Med J (Engl)."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:32:23Z","timestamp":1732023143000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304937"}},"subtitle":[],"editor":[{"given":"Paolo","family":"Aurello","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304937","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.23.24307798","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}